Jazz Pharmaceuticals (JAZZ) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Jazz Pharmaceuticals JAZZ is currently developing the following drugs: Jzp269, Cannabidiol Oral Solution, Epidiolex, Cbd-Os, Jzp926 Capsule, Cbd-Os, Xywav, Jzp258, Jzp3507, Onc206, Durvalumab, Lurbinectedin, Zepzelca, Jzp047, Onc206, Onc206: Dose 1, Onc206: Dose 2, Cbd-Os, Gwp42003-P, Carboplatin, Paclitaxel, Docetaxel, Zanidatamab, Trastuzumab, Pertuzumab, Jzp441, Zanidatamab, Gemcitabine, Zanidatamab, Capecitabine, Vinorelbine, Trastuzumab, Eribulin, Gemcitabine, Cisplatin, Durvalumab, Pembrolizumab, Zanidatamab, Pembrolizumab, Jzp898, Jzp258, Cannabidiol Oral Solution [Epidiolex], Jzp541, Lurbinectedin, Suvecaltamide, Jzp341, Dordaviprone, Jzp815, Gwp42003-P, Jzp150, Oxaliplatin, Cisplatin, Zanidatamab, Capecitabine, Trastuzumab, 5-Fluorouracil, Tislelizumab, Jzp385, Carboplatin, Etoposide, Atezolizumab, Lurbinectedin, Cannabidiol, Zanidatamab, Evorpacept, Nabiximols, Jzp-258. These drug candidates are in various stages of clinical development as the company works toward FDA approval.